A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03554031

Recruitment Status : Unknown

Verified May 2018 by GeneScience Pharmaceuticals Co., Ltd..
Recruitment status was: Recruiting

First Posted : June 12, 2018

Last Update Posted : June 12, 2018

Sponsor:

Collaborators:

Children's Hospital of Fudan University

Tongji medical college huazhong university of science & technology

Beijing Children's Hospital

Peking University First Hospital

Peking Union Medical College Hospital

The Children's Hospital of Zhejiang University School of Medicine

Information provided by (Responsible Party):

GeneScience Pharmaceuticals Co., Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	January 2020
Estimated Study Completion Date :	January 1, 2020

To Top